Artificial Heart Market Size, Share, and Industry Analysis By Type (Left Ventricular Assist Devices (LVADs), Total Artificial Heart, and Others), By Application (Bridge to Transplant (BTT), Bridge to Candidacy (BTC), Destination Therapy (DT), and Bridge to Recovery (BTR)), By End User (Hospitals, Specialty Clinics, and Others) and Regional Forecast, 2026-2034

The global artificial heart market size was valued at USD 3.53 billion in 2025. The market is projected to grow from USD 3.94 billion in 2026 to USD 9.41 billion by 2034, exhibiting a CAGR of 11.51% during the forecast period.

The global artificial heart market is expecting significant expansion owing to the incessantly aging population worldwide. Artificial hearts are medical devices similar to the normal functions of the human heart. This instrument is also known as cardiac assist devices. These devices are utilized in place of original heart pump blood adequately in heart failure, cardiac disease, or other major medical issues. These devices are used in both ways as temporary or permanent treatments depending on the individual’s requirements.

• According to the National Center for Biotechnology Information, only 2% of affected patients with heart failure receive new heart transplants.

Rising rate of occurrence of cardiac disease and growing geriatric population are driving the market growth. The cause of the rising disease is due to the adoption of improper lifestyles which is causing a deteriorating effect on individual health. Additionally, the implementation of advanced technologies in the system is impelling the market growth.

Artificial Heart Market Driver

Increasing Prevalence of Cardiovascular Diseases and Government Support and Healthcare Funding To Boost Market Growth

The growing aspect for market expansion is the increasing cardiovascular disorders (CVDs). These diseases may cause adverse effects on heart health. They cause significant cardiac damage, demanding complex treatments are contributing to adoption of the synthetic hearts. These synthetic hearts offer life-saving solutions for patients until heart transplants.

• According to Cardiology Research, about 60-94% of individuals with heart failure who are diagnosed with advanced –stage disease have died within a year.

Furthermore, several government, healthcare organizations, and healthcare institutions are investing in research of CVD. These investments are done in turns of improved prevention, diagnosis, and treating CVDs. The rising expenditure in R&D activities are helping in making advanced devices and approved for clinical trials, impending market growth.

Artificial Heart Market Restraint

High Cost of Artificial Hearts and Complications and Risks Associated with Implantation to Impede Market Growth

One of the off-putting factors for market impediment is the high cost of the synthetic devices. The expenditures related with surgical procedures may limit access to these technologies, particularly in emerging countries with low income propel. Furthermore, the implementation of cardiac assist devices carries risks such as infection, blood clot, and other issues are hindering the market growth.

• According to the National Center for Biotechnology Information, around 44% of patients with heart transplants died within five years, caused by graft failures.

In addition, the approval of processes for making new synthesis tools, along with the complex regulatory requirements might slow down the implementation of the newer technologies, consequently hampering the market growth.

Artificial Heart Market Opportunity

Development of more Affordable Artificial Hearts and Integration of Artificial Intelligence (AI) Bolster Market Growth

There is an opportunity to generate more cost-effective devices as technology advances. These advanced devices are improving the operation of the implementation of synthetic hearts in individuals. Hence, the tools can be more extensively available to individuals across different income groups, mainly in emerging markets. Furthermore, the integration of AI to monitor and handle the performance of cardiac assisted devices is impelling the market growth. They provide real-time data to healthcare providers, leading to better patient management and more effective treatment plans.

Additionally, there is growing development of biodegradable materials and rising demand for implementation of minimally invasive techniques. These aspects are presenting great chances for innovation in cardiac assist devices technology, which is improving patients’ outcomes as well as recovery times, and is supporting market growth.

Segmentation

Key Insights

The artificial heart market report covers the following key insights:

• Increasing prevalence of cardiovascular diseases, by Key Countries
• Government Expenditure on R&D, by Key Countries
• Drivers, Restraints, Trends, and Opportunities
• Investment Strategies Adopted by Key Players
• Consolidated SWOT Analysis of Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships)

Analysis by Product Type

Based on type, the market is divided into left ventricular assist Devices (LVADs), total artificial heart, and others.

The total artificial heart devices are intended to imitate the functionality of a human heart, which is crucial for patients. This segment is dominating the market due to its role that is similar to original heart patients suffering from last-stage heart failure.

• According to the National Center for Biotechnology Information, the Jarvik 7 (CardioWest) TAH as a BTR after a 10-year study involving 95 patients has a success rate of 79%.

Ventricular Assist Devices are gaining traction in the market, driven by its use as a BTT. VADs can serve as destination therapy for patients devoid of a heart transplant. The increasing utilization of the products is its success rate in making them suitable for clinical settings worldwide.

Analysis by Application

Based on application, the artificial heart market is divided into bridge to transplant (BTT), bridge to candidacy (BTC), destination therapy (DT), and bridge to recovery (BTR).

The bridge to transplant section is leading the market, driven by its use as a provisional support to patients with severe heart failure until a heart transplant. The BTT improves patients’ survival rates and quality of life, making it vital for managing heart failure.

The destination therapy segment is expecting significant growth owing to its utilization by individuals who cannot replace their heart. DT offers long-term support to patients and has expanded the scope of non-natural heart tools.

Analysis by End User

Based on end user, the artificial heart market is divided into hospitals, specialty clinics, and others.

The hospitals offer the availability of advanced healthcare facilities and presence of professional personnel. This segment offers complex operations and procedures, making them a critical component of the market.

Specialty clinics are also emerging as significant end-users in this market due to its major focus on CVD care. They are equipped with dedicated medical staff and equipment to perform cardiac assist devices transplants.

Regional Analysis

Based on geography, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America is ruling the market, caused by its robust healthcare infrastructure and adoption of advanced technologies. The region is performing strong collaborations between the various academic institutions and device manufacturers are improving tool’s functionality that foster rapid innovation and adoption. For instance, according to the Cardiology Research, over 3,000 patients are on the heart transplants waiting list and approximately 2,000 numbers of heart donors are available annually in the U.S.

Europe is witnessing significant market growth due to the presence of established regulatory frameworks and a longstanding history of medical research. Major cities in this region are benefitting from enhanced government support for healthcare infrastructure innovation and increasing spending on public health technology and device improvement are bolstering market expansion.

The Asia Pacific is experiencing fast growth in the market due to its increasing healthcare facilities. The region with high patient volumes and increasing middle class incomes are supporting the market growth. The improving accessibility of high-quality medical care with rising spending on research and development activities and adoption of new technologies, are fueling market growth.

Key Players Covered

The artificial heart market report includes the profiles of the following key players:

• SynCardia Systems, LLC (U.S.)
• CARMAT (France)
• Abbott (U.S.)
• RealHeart (Sweden)
• BiVACOR Inc. (U.S.)
• Jarvik Heart, Inc. (U.S.)
• LivaNova PLC (U.K.)
• Getinge (Sweden)

Key Industry Developments

• December 2024 – BiVACOR completed the first-phase of the FDA Early Feasibility Study between July and November 2024 successfully along with five patients who received the BiVACOR Total Artificial Heart (TAH). The main purpose of this study is to examine the safety and performance of the system as a bridge to donor heart transplant in patients.

June 2024 - IIT Kanpur developed an affordable artificial heart, named Hridayantr, in collaboration of students and the guidance of professors at the institute. The tool is made from titanium that is technically termed as the Left Ventricular Assist Device (LVAD). This device was designed to help individuals to pump blood effectively whose hearts are unable to function.